Using claims data instead of self-reports, a team of researchers in Germany evaluated adherence to endocrine therapy on recurrence and mortality in early breast cancer. High adherence to endocrine ...

Unopposed estrogen hormone therapy (E-HT) reduces breast cancer risk, while estrogen plus progestin hormone therapy (EP-HT) increases it, especially with long-term use. The study analyzed data from ...

After 3 years of follow-up in the Mammary Prevention 3 (MAP.3) randomized trial, women who took exemestane were 65% less likely than those who took a placebo to develop breast cancer. 8 With 7 years ...

The landscape of breast cancer detection continues to evolve, with medical understanding now emphasizing personalized knowledge of breast tissue over rigid examination routines. This shift reflects ...